Global monovaccine (Epstein-Barr virus) market potential, by Application (Mononucleosis, Endemic Burkitt’s lymphoma, Hodgkin’s lymphoma, Gastric carcinomas, Multiple sclerosis, and Nasopharyngeal Carcinoma) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be US$ 2.0 Bn, as highlighted in a new report published by Coherent Market Insights. Frequent research and development activities and funding by various organizations is expected to lead to the development of monovaccine in future.
Currently, there is no licensed vaccine for EBV. However, various universities and organizations are taking efforts to develop novel vaccines and fulfill unmet needs.
For instance, in March 2017, Cancer Research U.K. completed its phase 1b clinical trial of (Modified Vaccinia Ankara) MVA-EBNA1/LMP2 vaccine. It is being treated on nasopharyngeal cancer patients with positive Epstein-Barr virus infection.
In 2017, researchers from the University of Kansas School of Engineering and School of Pharmacy analyzed the genetics of human immune responses to develop basis of an effective vaccine or drug therapy against Epstein-Barr virus or EBV, the pathogen that causes infectious mononucleosis and infects around 90% of adults worldwide.
In January 2019, researchers and scientists from the German Cancer Research Center developed a new strategy for creating a vaccine that targets different EBV virus life phases and has the potential to provide effective protection against EBV infection.
Hence, frequent monovaccine development efforts by various universities is expected to result in development of novel vaccines and fulfill unmet needs in the near future.
Browse 10 Market Data Tables and 10 Figures spread through 84 Pages and in-depth TOC on Global Monovaccine (Epstein - Barr virus) Market by Application (Mononucleosis, Endemic Burkitt’s lymphoma, Hodgkin’s lymphoma, Gastric carcinomas, Multiple sclerosis, and Nasopharyngeal Carcinoma) and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa)
To know the latest trends and insights prevalent in the Monovaccine (Epstein - Barr virus) market, click the link below:
Various government organizations from different regions are taking efforts for the development of novel monovaccines (Epstein - Barr virus) and gaining approval.
For instance, in 2019, researchers from National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) determined how various antibodies induced by Epstein-Barr virus (EBV) block infection of cells grown in the laboratory.
Researchers used this information for development of novel vaccine candidates in animals, elicited potent anti-EBV antibody responses that blocked infection of cell types involved in EBV-associated cancers.
Key Takeaways of the Global Monovaccine (Epstein-Barr virus) Market:
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Email: [email protected]
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.